Ameluz
Generic name: aminolevulinic acid
Treatment for: Actinic Keratosis
FDA Accepts Filing of Ameluz and BFRhodoLED New Drug Application
Leverkusen, Germany, 11 September 2015 – Biofrontera AG (FSE/AIM:B8F), the biopharmaceutical company focusing on sun-induced skin cancer, has today been informed that the Food and Drug Administration (FDA), the responsible US government agency, has accepted filing of the New Drug Application (NDA) of Biofrontera’s antiskin cancer drug Ameluz combined with the PDT lamp BF-RhodoLED®.
This constitutes the first key step in the approval process of Ameluz and BF-RhodoLED® in the USA. Successfully passing this stage is a major milestone in the approval process and one of the most important steps in the history of the company. With the positive decision, an FDA Review team is assigned to evaluate the research Biofrontera has performed on the drug’s safety and effectiveness as well as the control measures in place to warrant the quality of the products. Within 5-6 months, the FDA will now prepare the mid-term review that will identify any outstanding issues and therefore provide a good indication for the timely approvability of the products.
Source: Biofrontera AG
Posted: September 2015
Related articles
- Biofrontera Announces U.S. FDA Approval of Ameluz and Activating BF-RhodoLED Device for Treatment of Actinic Keratosis - May 11, 2016
- Biofrontera Submits New Drug Application for Ameluz to FDA - July 13, 2015
Ameluz (aminolevulinic acid) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.